When, if ever, would you consider lenvatinib + pembrolizumab as first line therapy for patients with stage IV microsatellite stable endometrial cancer?
Are there certain patient or disease related factors that would lead you to incorporate lenvatinib + pembrolizumab earlier?
Community PollStarted
Would you consider lenvatinib + pembrolizumab as first line therapy for patients with stage IV microsatellite stable endometrial cancer?
48 physicians have voted
Join Mednetto vote and see how they answered.
1 Answer
Mednet MemberInvited Expert
Gynecologic Oncology · UCSD Moores Cancer Center
Answered on
Outside of a clinical trial, I have not incorporated lenvatinib and pembrolizumab therapy as 1L therapy for pMMR endometrial cancer patients. This question will be answered by the LEAP-001 trial, which has completed accrual.
Join for free or sign in to see the full answer